
Sasa Jankovic
Frrelance Medical/Health Journalist/Editor/Copywriter and Author at The Pharmaceutical Journal
Yorkshire-born half Scouse half Serb. Award-winning health journalist. Journalling-for-mental-health tutor. Buy me a ☕️ https://t.co/HAfLUu1UWn
Articles
-
2 weeks ago |
hospitalhealthcare.com | Sasa Jankovic
The UK Government has pledged nearly £450m in its new Urgent and Emergency Care Plan 2025/26 (UEC plan), to address longstanding pressures across the NHS by reducing hospital admissions and lengthy discharge, tackling ambulance handover delays and eliminating corridor care. Ahead of the anticipated publication of the new NHS 10-Year Health Plan, the UEC plan emphasises shifting patient care into more appropriate settings.
-
1 month ago |
pharmaceutical-journal.com | Sasa Jankovic
The use of antidepressants — particularly selective serotonin re-uptake inhibitors (SSRIs) — are associated with a “statistically substantial increased risk” of postural hypotension (PH) in older people during the first 28 days of use, according to the results of a study.
-
1 month ago |
pharmaceutical-journal.com | Antimicrobial resistance |Sasa Jankovic
More than three-quarters (79%) of pharmacies receive requests for unnecessary antibiotics from patients for minor ailments, such as colds, at least once a day, via over-the-counter drugs or during Pharmacy First consultations, a survey conducted by the National Pharmacy Association (NPA) has revealed.
-
2 months ago |
pharmaceutical-journal.com | Sasa Jankovic
The Medicines and Healthcare products Regulatory Agency (MHRA) is reviewing blood monitoring requirements for patients using clozapine and will seek views on how to improve awareness and management of the risks associated with the antipsychotic medicine, a health minister has said.
-
2 months ago |
pharmaceutical-journal.com | Sasa Jankovic
A new treatment for advanced bowel cancer has been approved by the National Institute for Health and Care Excellence (NICE) and made available on the NHS, reversing previous draft guidance that did not recommend the combined immunotherapies nivolumab (Opdivo) and ipilimumab (Yervoy). In documents supporting its decision, NICE said that clinical evidence showed the dual treatment to be effective against standard care, which is either chemotherapy or pembrolizumab.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 6K
- DMs Open
- Yes

There goes my hero 😞

Medicine #pollution of rivers in English national parks appears to pose risks to ecological and human health through recreational water use - via @PJOnline_News https://t.co/wLyJxk1Rdb

How ‘woke’ #marketing lets #fastfashion brands get away with environmental and labour abuses - "the underlying message remains the same: women can make the world better by shopping" https://t.co/zRvWlr9JRo via @ConversationUK